ChemicalBook
Chinese Japanese Germany Korea

BIBW2992 DiMaleate

Description Mechanism of Action
BIBW2992 DiMaleate
BIBW2992 DiMaleate structure
CAS No.
850140-73-7
Chemical Name:
BIBW2992 DiMaleate
Synonyms
BIBW2992-MA2;BIBW2992 DiMaleate;Afatinib (maleate);Afatinib (diMaleate);Afatinib double Maleate;Afatinib dimaleate, >=99%;Afatinib (BIBW2992) Dimaleate;Afatinib (diMaleate), BIBW2992;BIBW2992-MA2 (Afatinib dimaleate);Afatinib dimaleate(BIBW2992,Gilotrif)
CBNumber:
CB22630067
Molecular Formula:
C32H33ClFN5O11
Formula Weight:
718.0827232
MOL File:
850140-73-7.mol

BIBW2992 DiMaleate Properties

FDA UNII
V1T5K7RZ0B
SAFETY
  • Risk and Safety Statements
HS Code  29339900

BIBW2992 DiMaleate price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 21567 Afatinib (maleate) ≥95% 850140-73-7 250mg $75 2018-11-19 Buy
Cayman Chemical 21567 Afatinib (maleate) ≥95% 850140-73-7 500mg $143 2018-11-19 Buy
Cayman Chemical 21567 Afatinib (maleate) ≥95% 850140-73-7 1g $270 2018-11-19 Buy
Cayman Chemical 21567 Afatinib (maleate) ≥95% 850140-73-7 5g $825 2018-11-19 Buy

BIBW2992 DiMaleate Chemical Properties,Uses,Production

Description

Afatinib dimaleate (Tovok; BIBW2992; Gilotrif) is a salt form of Afatinib. Afatinib is a second-generation, orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases.

Mechanism of Action

Afatinib downregulates ErbB signalling by covalently binding to the kinase domains of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation; it also inhibits transphosphorylation of HER3. Afatinib is approved as monotherapy for the treatment of EGFR tyrosine kinase inhibitor (TKI)-naïve adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations in the EU, and for the first-line treatment of patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test in the US.

Definition

ChEBI: A maleate salt obtained by combining afatinib with two molar equivalents of maleic acid. Used for the first-line treatment of patients with metastatic non-small cell lung cancer.

BIBW2992 DiMaleate Preparation Products And Raw materials

Raw materials

Preparation Products


BIBW2992 DiMaleate Suppliers

Global( 198)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 sales@tianpharm.com CHINA 305 58
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 sales@frappschem.com China 886 50
Capot Chemical Co.,Ltd.
+86-571-85586718
+86-571-85864795 sales@capotchem.com China 19927 60
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37122233
+86-21-37127788 Candy@bj-chem.com CHINA 497 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22626 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24698 60
Lianyungang happen teng technology co., LTD
15950718863
wang666xt@163.com CHINA 296 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30050 58
Zhejiang ZETian Fine Chemicals Co. LTD
+86-18957127338
sales@zetchem.com CHINA 2886 58

Related articles


View Lastest Price from BIBW2992 DiMaleate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-08-15 Afatinib dimaleate
850140-73-7
US $0.00-0.00 / KG 1g 99% 50kg/month Beijing Yibai Biotechnology Co., Ltd
2018-08-21 BIBW2992 DiMaleate
850140-73-7
US $7.00 / KG 1KG 99% 1000KG career henan chemical co
2018-08-16 Afatinib diMaleate
850140-73-7
US $1.00 / KG 1KG 98% 500kg career henan chemical co

850140-73-7(BIBW2992 DiMaleate)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved